Form 8-K

8-K — Zeo ScientifiX, Inc.

Accession: 0001829126-26-009583

Filed: 2026-09-01

Period: 2026-09-01

CIK: 0001557376

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — zeoscientifix_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (zeoscientifix_ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: zeoscientifix_8k.htm · Sequence: 1

false

0001557376

2026-09-01

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 1, 2026

ZEO SCIENTIFIX, INC.

(Exact name of registrant as specified in its charter)

Nevada

000-55008

47-4180540

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

3321 College Avenue, Suite 246

Davie, Florida

33314

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s telephone number, including area code: (888) 963-7881

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class

Trading Symbol

Name of each exchange on which registered

None

N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

used in this Current Report on Form 8-K (this “Report”), and unless otherwise indicated, the terms “the Company,”

“ZEO,” “we,” “us” and “our” refer to Zeo ScientifiX, Inc.

Item

8.01 Other Events.

September 1, 2026, ZEO issued a press release announcing the faculty and guest speaker lineup for the Company’s inaugural ZEO

Xperience, a three-day immersive regenerative medicine educational experience for healthcare professionals taking place October 23–25, 2026, at the Pier Sixty-Six Resort in

Fort Lauderdale, Florida.

copy of the press release is included as Exhibit 99.1 to this Report.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits

Exhibit No.

Description

99.1

Press Release, dated September 1, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 1, 2026

ZEO SCIENTIFIX, INC.

By:

/s/ Ian T. Bothwell

Ian T. Bothwell

Chief Executive Officer and Chief Financial Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: zeoscientifix_ex99-1.htm · Sequence: 2

Exhibit 99.1

ZEO ScientifiX Announces Multidisciplinary Expert Faculty Lineup for the ZEO Xperience

Leading physicians, scientists, regulatory experts, and healthcare innovators will convene October 23–25 at Fort Lauderdale’s Pier Sixty-Six Resort + Marina for three days of regenerative medicine education, hands-on clinical training, and interdisciplinary collaboration.

FORT LAUDERDALE, FLORIDA — September 1, 2026 — ZEO ScientifiX, Inc. (OTCQB: ZEOX) (“ZEO ScientifiX” or the “Company”) today announced the multidisciplinary faculty and guest speaker lineup for the inaugural ZEO Xperience, a three-day immersive regenerative medicine event for healthcare professionals taking place October 23–25, 2026, at Pier Sixty-Six Resort + Marina in Fort Lauderdale, Florida.

Bringing together physicians, scientists, regulatory professionals, clinical educators, and healthcare innovators from across the country, the ZEO Xperience is designed to create a setting where healthcare professionals can explore regenerative medicine from multiple perspectives, including the underlying science and manufacturing of biologics, the current regulatory landscape, current clinical best practices for a variety of applications, and practice implementation.

The announced lineup reflects the interdisciplinary nature of regenerative medicine itself, with experts representing dermatology, orthopedics, sports medicine, regenerative plastic surgery, cardiovascular medicine, regulatory law, regenerative science, intimate health, aesthetics, and healthcare business development.

“Regenerative medicine does not exist within a single specialty, and we did not want the ZEO Xperience to be built around a single perspective,” said Sean Vega-Stanton, M.S., General Manager of ZEO ScientifiX. “We are bringing together physicians, scientists, regulatory experts, and industry leaders who approach this field from very different angles. That diversity is what makes the faculty so exciting. Attendees will have the opportunity to understand the science, discuss the regulatory environment, learn clinical techniques, and hear directly from experts who are applying these concepts across multiple areas of medicine.”

Hands-On Training Led by Specialized Clinical Faculty

A defining component of the ZEO Xperience will take place on Saturday, October 24, when attendees transition from classroom-based education into focused clinical training.

The Saturday Training faculty includes:

●

Stacy Chimento, M.D., FAAD — Aesthetics & Hair

●

Michael Magee, M.D. — Orthopedics, including ligaments and small joints

●

Joseph Banno, M.D. — Male Intimate Health

●

Carolyn DeLucia, M.D. — Female Intimate Health

●

Constantino Mendieta, M.D. — Regenerative Plastic Surgery

Training will span regenerative aesthetics, orthopedic applications, image-guided and joint-focused techniques, intimate health, and other physician-directed applications, creating opportunities for attendees to learn directly from clinicians with experience in their respective specialties.

Rather than separating scientific education from clinical implementation, the ZEO Xperience was intentionally structured to connect the two.

“Physicians are asking increasingly sophisticated questions about regenerative medicine, and meaningful education has to meet that demand,” said Ian Bothwell, CEO of ZEO ScientifiX. “That means understanding where biologics come from and how they are manufactured, but it also means understanding regulation, patient selection, clinical technique, and how these technologies fit responsibly within a medical practice. Bringing this caliber and range of expertise into one program allows for a much more complete conversation.”

Expanding ZEO ScientifiX’s Investment in Physician Education

The ZEO Xperience builds on ZEO ScientifiX’s expanding physician-education platform, which includes Master Classes, webinars, scientific programming, clinical collaborations, national educational partnerships, and multidisciplinary faculty engagement.

By bringing these efforts together into a single immersive weekend, the Company aims to create an environment where healthcare professionals can engage directly with experts, ask difficult questions, exchange clinical perspectives, and build relationships with other providers exploring the evolving regenerative medicine field.

“The goal is not simply to put speakers on a stage,” Vega-Stanton added. “The goal is to put the right people in the same room and create meaningful interaction between them. A dermatologist may see regenerative medicine differently than an orthopedic physician, a scientist, a plastic surgeon, or a regulatory attorney. When those perspectives come together, the conversation becomes significantly more valuable. That is the experience we are building.”

Attendance for the inaugural ZEO Xperience is intentionally limited to support meaningful interaction between attendees, faculty, exhibitors, and participating healthcare professionals.

Registration is currently open for the October 23–25, 2026 ZEO Xperience at Pier Sixty-Six Resort + Marina in Fort Lauderdale, Florida. Full-event and select single-day attendance options are available.

Faculty, speakers, programming, and schedule are subject to change.

About ZEO ScientifiX, Inc. (OTCQB: ZEOX)

ZEO ScientifiX, Inc. (OTCQB: ZEOX) is an SEC-reporting, clinical-stage biopharmaceutical company focused on the research, development, and manufacturing of regenerative biologics. Operating from Nova Southeastern University’s Center for Collaborative Research in Davie, Florida, the Company works at the intersection of scientific innovation, regenerative biologics, and physician education.

Through its scientific initiatives, educational programming, clinical collaborations, and relationships with healthcare professionals, ZEO ScientifiX is focused on supporting the responsible advancement of regenerative medicine and helping bridge emerging science with clinical practice.

For more information, visit ZEO ScientifiX’s website.

Forward-Looking Statements

Certain statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties.

Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Actual results could vary materially. ZEO ScientifiX has no intention and specifically disclaims any duty to update the information contained in this press release except as may be required by applicable law.

Media Contact

ZEO ScientifiX, Inc.

Sean Vega-Stanton

Sean@zeoscientifix.com

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Sep. 01, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Sep. 01, 2026

Entity File Number

000-55008

Entity Registrant Name

ZEO SCIENTIFIX, INC.

Entity Central Index Key

0001557376

Entity Tax Identification Number

47-4180540

Entity Incorporation, State or Country Code

Entity Address, Address Line One

3321 College Avenue

Entity Address, Address Line Two

Suite 246

Entity Address, City or Town

Davie

Entity Address, State or Province

Entity Address, Postal Zip Code

33314

City Area Code

(888)

Local Phone Number

963-7881

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration